Market Cap (In USD)
1.19 Million
Revenue (In USD)
-
Net Income (In USD)
-11.96 Million
Avg. Volume
3044.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.001-1.01
- PE
- -0.0938
- EPS
- -4.37
- Beta Value
- 1.381
- ISIN
- US19249J3077
- CUSIP
- 19249J109
- CIK
- 1522602
- Shares
- 2906930.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Pinchas Cohen Dean, M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.cohbar.com
- Ipo Date
- 2017-12-15
- Details
- CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
More Stocks
-
LSEAW
-
TESBTessenderlo Group NV
TESB
-
ALL
-
IFMInfomedia Ltd
IFM
-
FAXXF
-
000063ZTE Corporation
000063
-
VLS
-
BGOBango PLC
BGO